D&O

Blade Air Mobility Reports Fiscal Third Quarter Ended June 30, 2021 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, August 16, 2021
Transportation, Travel, Other Transport, Air, Other Energy, Transport, Utilities, Alternative Energy, Environment, Energy, Other Travel, Aircraft, Assault, EBITDA, Heyburn, Table, Holocene, D&O, COVID-19, Company, Adjustment, Mission statement, Â, GAAP, Travel, Insurance, Acquisition, Growth, JFK, Three Months Gone, Western literature, Beta Technologies, MagniX, EVA, Nasdaq, Comparable, City, Airport, Airline, Tutoring, Animal, Pharmaceutical industry

Blade Air Mobility, Inc. (Nasdaq:BLDE, Blade or the Company), a technology-powered air mobility platform, today announced financial results for the fiscal third quarter ended June 30, 2021.

Key Points: 
  • Blade Air Mobility, Inc. (Nasdaq:BLDE, Blade or the Company), a technology-powered air mobility platform, today announced financial results for the fiscal third quarter ended June 30, 2021.
  • After two months of operation, our current weekly volume is well ahead of the same point in our initial 2019 launch.
  • Adjusted EBITDA and Comparable Adjusted EBITDA have been reconciled to the nearest GAAP measure in the tables within this press release.
  • For the Three Months Ended June 30,
    For the Nine Months Ended June 30,

IGI’s Existing Financial Strength Ratings Assigned to new Malta-based European Subsidiary

Retrieved on: 
Friday, August 13, 2021
Professional Services, Insurance, Finance, Forward-looking statement, NASDAQ, Judgement, D&O, SE, Company, Movement, Private Securities Litigation Reform Act, COVID-19, S&P, Annual report, SEC, Malta Financial Services Authority, D, Port Terminal Station, AM Best, Form 20-F, S&P Global Ratings, Engineering, International, Industry, IGI, Insurance, Risk management

International General Insurance Holdings Ltd. (IGI or the Company) (NASDAQ: IGIC) today announced that the financial strength ratings of the IGI group have been assigned to the Companys new European subsidiary in Malta.

Key Points: 
  • International General Insurance Holdings Ltd. (IGI or the Company) (NASDAQ: IGIC) today announced that the financial strength ratings of the IGI group have been assigned to the Companys new European subsidiary in Malta.
  • S&P Global Ratings has assigned an A- financial strength rating to International General Insurance Company (Europe) SE (IGI Europe), while AM Best has assigned an A (Excellent) financial strength rating to the Malta-based subsidiary.
  • IGI Europe CEO Keith Mallia-Milanes said, Securing these equalized ratings from S&P and AM Best is an important step forward for IGI Europe.
  • Our European subsidiary is obviously strategically important to the IGI group as it provides the Company access to business across Europe.

Repare Therapeutics Provides Business Update and Reports Second Quarter 2021 Financial Results

Retrieved on: 
Thursday, August 12, 2021
FDA, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Forward-looking statement, Net, U.S. Securities and Exchange Commission, Talazoparib, D&O, ATR, Bristol Myers Squibb, Research, Company, Risk, Private Securities Litigation Reform Act, PARP, Cancer, COVID-19, Therapy, Review, CRISPR, DNA, SEC, D, Security (finance), Patient, IPO, Neoplasm, Safety, PKMYT1, AMF, Genome, Pharmaceutical industry, Medical imaging, Lithium, Repare Therapeutics’ SNIPRx® Platform, Repare Therapeutics, Inc., REPARE THERAPEUTICS’ SNIPRX® PLATFORM, REPARE THERAPEUTICS, INC.

Repare Therapeutics Inc. (Repare or the Company) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today reported financial results for the second quarter ended June 30, 2021.

Key Points: 
  • Repare Therapeutics Inc. (Repare or the Company) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today reported financial results for the second quarter ended June 30, 2021.
  • The Company plans to disclose initial results from the monotherapy arm early in the fourth quarter of 2021.
  • Second Quarter 2021 Financial Results:
    Cash and cash equivalents, restricted cash and marketable securities: Cash and cash equivalents, restricted cash and marketable securities as of June 30, 2021 were $301.0 million.
  • Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics.

IGI Announces Semi-Annual Ordinary Common Share Dividend

Retrieved on: 
Thursday, August 12, 2021
Professional Services, Insurance, Finance, Forward-looking statement, NASDAQ, Judgement, D&O, Company, Movement, Private Securities Litigation Reform Act, COVID-19, Annual report, SEC, D, Board, Board of directors, Port Terminal Station, AM Best, Engineering, Form 20-F, S&P Global Ratings, International, Industry, IGI, Risk management

---

Key Points: 
  • International General Insurance Holdings Ltd. (IGI or the Company) (NASDAQ: IGIC) today announced that its Board of Directors has declared an ordinary common share dividend of $0.16 per share for the period January 1, 2021 June 30, 2021.
  • IGI is an international specialty risks commercial insurer and reinsurer underwriting a diverse portfolio of specialty lines.
  • Registered in Bermuda, with operations in Bermuda, London, Malta Dubai, Amman, Labuan and Casablanca, IGI aims to deliver outstanding levels of service to clients and brokers.
  • IGI is rated A (Excellent)/Stable by AM Best and A-/Stable by S&P Global Ratings.

PolyPid Ltd. Reports Second Quarter 2021 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, August 11, 2021
SHIELD, Hospital, Regulation of tobacco by the U.S. Food and Drug Administration, Brain, Safety, Company, Patient, Hospital-acquired infection, Food, PLEX, Recurrence, Conference, Particle-size distribution, Program, Cancer, Infection, Colorectal surgery, Financial result, SSIS, D&O, Polypide, Surgery, Insurance, NDA, Docetaxel, FDA, GLOBE, Marketing, Research, Communication, Medical imaging, Pharmaceutical industry, Animal, Lithium, Cryptocurrency

PETACH TIKVA, Israel, Aug. 11, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharma company aiming to improve surgical outcomes through locally administered, controlled, extended-release therapeutics, today provided a corporate update and reported financial results for the three and six months ended June 30, 2021.

Key Points: 
  • PETACH TIKVA,Israel, Aug. 11, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharma company aiming to improve surgical outcomes through locally administered, controlled, extended-release therapeutics, today provided a corporate update and reported financial results for the three and six months ended June 30, 2021.
  • Enrollment is also advancing as anticipated in SHIELD II, the second of two Phase 3 clinical trials for D-PLEX100 in abdominal surgery (soft tissue).
  • General and administrative expenses for the second quarter of 2021 were $2.4 million, compared to $2.6 million in the prior year period.
  • PolyPid continues to expect that its cash on hand will be sufficient to fund operations into the second half of 2022.

CohBar Reports Second Quarter 2021 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, August 10, 2021
Biotechnology, Industry, Therapy, Degenerative disease, Acute respiratory distress syndrome, News, Safety, Baptist General Association of Virginia, MBT, D, Trial of the century, Private Securities Litigation Reform Act, Risk, U.S. Securities and Exchange Commission, Treatment, Conference, Security (finance), Mitochondrion, Drug discovery, Forward-looking statement, Clinical trial, D&O, COVID-19, Home, Conditional sentence, Non-alcoholic fatty liver disease, Research, Prevalence, Idiopathic pulmonary fibrosis, Investment, NASDAQ, GLOBE, ALT, Biomarker, AST, Liver, Peptide, IPF, NASH, Growth, ID, Pharmaceutical industry

The study met its primary endpoints as CB4211 was well-tolerated and appeared safe with no serious adverse events.

Key Points: 
  • The study met its primary endpoints as CB4211 was well-tolerated and appeared safe with no serious adverse events.
  • There was a trend towards lower body weight in the CB4211 group after four weeks of treatment.
  • Cash and Investments: CohBar had cash and investments of $13.8 million as of June 30, 2021, compared to $21 million as of December 31, 2020.
  • Please visit https://us02web.zoom.us/j/84796437737?pwd=R2t0eEFRVDVlVDVZMTdhT0pGWVVsUT09 and enter password CWBR, or
    Go to www.cohbar.com and click on CohBar Q2 2021 Investor Presentation at the top of homepage.

Satsuma Pharmaceuticals Reports Second Quarter 2021 Financial Results and Recent Business Highlights

Retrieved on: 
Tuesday, August 10, 2021
ASCEND, Triangle Park (Quezon City), Dihydroergotamine, Achievement, New Drug Application, Safety, Company, Patient, Migraine, D, Pain, Freedom, U.S. Securities and Exchange Commission, Risk, Security (finance), DHE, Program, Phonophobia, Clinical trial, D&O, Photophobia, COVID-19, Plasma, Nausea, Terminology, EMERGE, NDA, Nasdaq, FDA, GLOBE, Research, Pharmaceutical industry, Renewable energy

SOUTH SAN FRANCISCO, Calif., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today reported financial results for the second quarter of 2021 and summarized recent business highlights.

Key Points: 
  • (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today reported financial results for the second quarter of 2021 and summarized recent business highlights.
  • Research and development expenses were $8.4 million for the second quarter 2021, compared to $8.8 million for the same period of 2020.
  • General and administrative expenses were $3.4 million for the second quarter 2021, compared to $2.7 million for the same period of 2020.
  • This press release contains forward-looking statements concerning the business, operations and financial performance and condition of Satsuma Pharmaceuticals, Inc. (the Company), as well as the Companys plans, objectives and expectations for its business operations and financial performance and condition.